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cholecystectomyAbstract Background: This study evaluated the efficacy of transdermal nicotine (TDN) delivery
system (15 mg/16 h) or transdermal melatonin (TDM) delivery system (7 mg) 2 h preoperatively
for acute postoperative pain after laparoscopic cholecystectomy compared to placebo group (C).
Methods: Sixty female non-smoker patients, aged 18–50 years and ASA I and II undergoing elec-
tive laparoscopic cholecystectomy under general anesthesia were included in this randomized con-
trolled double-blind study. Patients were randomly divided into 3 groups 20 each, and C group
patients received transdermal placebo patch, TDN group (15 mg/16 h) and TDM group
(7 mg/8 h). Assessment of postoperative pain, sedation, hemodynamic variables such as HR and
MAP, postoperative monitoring of arterial SpO2 and side effects (e.g. nausea, vomiting, pruritus,
respiratory depression and hemodynamic instability) were done 30 min, 1, 2, 6 and 12 h postoper-
atively. Postoperative Patient’s and Surgeons’ satisfaction, Intraoperative bleeding and plasma
cortisol (lg/dl) 2 h postoperatively were also assessed.
Results: There was a significant reduction in the VAS score, total pethidine requirements (mg) and
significantly higher patient’s satisfaction in TDN and TDM groups when compared with the C
group postoperatively. The sedation score and surgeons’ satisfaction were significantly higher asso-
ciated with a significant decrease in MAP and Intraoperative bleeding in TDM group compared to
C and TDN groups postoperatively. Significant nausea and vomiting in TDN group and significant
sedation in TDM group were recorded.
Conclusion: The use of preoperative TDN (15 mg/16 h) or TDM (7 mg/8 h) was an effective and a
safe adjuvant for acute pain after surgery.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intraoperative and postoperative noxious inputs may cause
central sensitization, but analgesic interventions given before
the noxious stimulus may attenuate or block sensitization [1].
Preventing the establishment of altered central processing by
analgesic treatment may result in short-term (e.g., reduction
in postoperative pain and accelerated recovery) and long-
term (e.g., reduction in chronic pain and improvement in
health related quality of life) benefits during a patient’s conva-
lescence [2]. Early postoperative pain is the most common
complaint after elective laparoscopic cholecystectomy. In
17–41% of the patients, pain is the main reason for overnight
hospital stay after day case surgery [3]. Intense acute pain after
laparoscopic cholecystectomy might predict the development
of chronic pain (e.g. post-laparoscopic cholecystectomy
syndrome) [4]. These concepts suggested a possible study
design; effective analgesia starts before incision and covers
both the period of surgery and the postoperative period.
Transdermal drug delivery offers the potential benefits of
simplicity, efficacy and patient acceptance. In theory, a
transdermal delivery system can provide a stable serum
concentration for an extended period of time with acceptable
interpatients’ variability [5].
Nicotine, a potent stimulant found in cigarette smoke, was
found to have analgesic properties [6]. Nicotine acts on nico-
tinic cholinergic receptors, which are found in the central ner-
vous system, autonomic ganglia, the neuromuscular junction,
as well as in several non-neuronal tissues [7]. Nicotine reduced
nociceptive input to the superficial and deep dorsal horn and
provides support for a4b2 and a7 nicotinic-mediated antinoci-
ceptive actions [8]. Nicotine acts on nAChRs in both the brain
and the spinal cord to activate spinal cord descending inhibi-
tory pain pathways [7]. Nicotine-mediated analgesia is thought
to involve, at least in part, local release of norepinephrine, with
activation of a2-adrenergic receptors [9]. Morphine activates a
descending inhibitory system, leading to increased release of
endogenous acetylcholine in the spinal cord, thereby produc-
ing analgesia through activation of spinal muscarinic and nico-
tinic receptors [10]. Nicotine may also produce analgesia by
release of endogenous opioids [11]. Furthermore, nicotine
has anti-inflammatory actions that could reduce pain [12,13].
Smokers would not experience pain relief from nicotine
because of chronic exposure to nicotine and receptor inactiva-
tion [14]. Only full-strength nicotine patches (15 mg/16 h or
21 mg/24 h) are subsidized on the Pharmaceutical Benefits
Scheme (PBS) [15].
Melatonin (N-acetyl-5-methoxytryptamine, MT) is a hor-
mone secreted primarily by the pineal gland in a circadian fash-
ion. The synthesis and secretion of MT are induced by darkness
and suppressed by light through retinal nerve fibers projecting
to the suprachiasmatic nucleus of hypothalamus, then to the
superior cervical ganglion and finally to the pineal gland. Dur-
ing the night, the mean endogenous plasma concentration of
MT is 50–70 pg/mL (216–302 pmol/L) in young adults. In
daylight hours, the mean MT plasma concentration is typically
<10 pg/mL (43 pmol/L). PlasmaMT levels begin to increase at
2100 h, peak between 0200 and 0400 h, and return to baseline
at 0700–0900 h [16]. MT has a short plasma elimination half-
life, 45 min and when administered orally, shows low and
variable bioavailability due to extensive first-pass metabolismand/or variable absorption [17]. Transdermal delivery system
for melatonin (TDM) results in sustained plasma MT levels
that can be tailored to the normal physiological range and
avoid the first-pass metabolism. TDM is intended to be worn
for 8 h [18]. Melatonin has sedative, anxiolytic, analgesic, anti-
hypertensive, anti‐inflammatory, chronobiotic and oncostatic
effects and potent antioxidant properties [19]. Melatonin exerts
its analgesic effects through augmentation of GABAergic
systems and morphine anti-nociception, enhancing
GABAinduced currents and inhibiting glycine effects [20].
Melatonin may enhance the levels of bendorphins and the
anti-nociception induced by delta opioid receptor agonists
and could activate MT2 melatonin receptors in the dorsal horn
of the spinal cord [21,22]. The long-lasting analgesia induced by
melatonin can be blocked by naloxone suggests that opioid
receptors are involved in actions of melatonin [23].
The stress response to surgery is characterized by increased
secretion of pituitary hormones and activation of the sympa-
thetic nervous system. The changes in the pituitary secretions
have secondary effects on hormone secretion from target
organs (increased secretion of cortisol from the adrenal cortex)
[24].
In this randomized, double-blind, placebo-controlled study,
our primary objective was to compare the TDN patches to
TDM patches for relieving postoperative pain after laparo-
scopic cholecystectomy under general anesthesia to detect a
mean difference of total analgesic (pethidine) consumption.
And our secondary goal was to compare the effects of TDN
patches to TDM patches on prolongation of first analgesic
requirement time, pain score, sedation score, stress response,
patient satisfactory score, surgeon satisfactory score, postoper-
ative monitoring of heart rate, mean arterial blood pressure,
arterial SpO2 and side effects (e.g. nausea, vomiting, pruritus,
respiratory depression and hemodynamic instability).
2. Methods
This study was designed to be a randomized, placebo-
controlled, double-blind parallel study in which the patients,
investigators, anesthesiologists and the surgeons were blinded
to the given treatment. This study was conducted in Ain-
Shams university hospitals, from April 2013 to July 2015, on
60 female non-smoker patients aged between 18 and 50 years
old of ASA physical status I and II of 70–90 kg body weight
and height 160–180 cm undergoing elective laparoscopic chole-
cystectomy under general anesthesia. The study protocol was
approved from the institutional ethical committee and written
informed consent was obtained from all the patients (see
Table 1).
Patients with impaired kidney or liver functions, history of
cardiac or central nervous system disease, history of smoking,
history of drug or alcohol abuse, history of chronic pain or
daily intake of analgesics, uncontrolled medical disease (dia-
betes mellitus and hypertension), history of intake of non-
steroidal anti-inflammatory drugs or opioids within 24 h
before surgery or allergy to the used medications, coagulation
defect, local infection at the site of application of transdermal
patch, patient refusal or duration of surgery more than
120 min were excluded from the study.
Patients were randomly divided into 3 groups, C group
(n= 20) each patient received transdermal placebo patch,
Table 1 Ramsay sedation score.
Score Observation
1 Anxious, agitated or restless
2 Cooperative, oriented and tranquil
3 Responsive to commands
4 Asleep, but with brisk response to light glabellar tap or
loud auditory stimulus
5 Asleep, sluggish response to glabellar tap or auditory
stimulus
6 Asleep, no response
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peutic system-nicotine (15 mg/16 h) and TDM group (n= 20)
each patient received transdermal therapeutic system-
melatonin (7 mg/8 h). Randomization was done using
computer-generated number table of random numbers in a
1:1 ratio and conducted using sequentially numbered, opaque
and sealed envelope (SNOSE). All patches were placed 2 h pre-
operatively and were applied to the skin in the subclavicular
area and the area was not shaved to maintain the integrity of
the skin to maintain normal absorption (if necessary hair was
only clipped from the patch site prior to application). The patch
was removed 12 h post-operatively. In this study we used iden-
tical placebo patches assembled by the hospital pharmacy, we
used Nicorette invisi 15 mg patch releasing 15 mg of nicotine
over 16 h, produced by Lohmann Therapie-System, Germany,
and we used melatonin sleep patch from Respro LabsTM con-
taining 7 mg of melatonin. Active patches containing nicotine
or melatonin were indistinguishable from placebo patches, cov-
ered with adhesive plaster to confirm fixation and to blind the
anesthetists and observers for the type of the used patches.
The study drugs were prepared by the anesthesia resident not
involved in any other part of the study.
Before any patch placement a preoperative visit was done
to all patients to assess patient fitness for operation, to allevi-
ate anxiety, to inform them about transdermal patches (its effi-
cacy in the treatment of postoperative pain, its possible side
effects and method of application) and to make them familiar-
ized with 10 cm marked visual analogue scale (VAS) for post-
operative assessment of pain, where 0 cm defines no pain and
10 cm defines the maximum intolerable pain. The patients were
also assured that they would receive intramuscular injection
(IM) of pethidine 0.5 mg/kg once they start to first experienced
pain postoperatively (Patients with (VAS > 3). Time to the
first request for analgesic and the total pethidine consumption
(mg) in 12 h postoperatively was recorded.
The general anesthesia technique was standardized for all
the patients as well as monitors including 5 lead ECG, non-
invasive blood pressure (NIBP) monitor, pulse oximetry and
capnography after intubation using Datascope monitors. Neu-
romuscular function was also monitored using a peripheral
nerve stimulator. After establishing an intravenous (IV) line,
induction of general anesthesia with fentanyl (2 ug/kg) and
sleeping dose of propofol followed by rocuronium (0.6 mg/kg)
to facilitate orotracheal intubation was done. Anesthesia was
maintained using sevoflurane in oxygen and air. Granisetron
(1 mg IV) was given as a prophylactic antiemetic. At the end
of the surgery, the residual neuromuscular paralysis was
antagonized with neostigmine (0.05 mg/kg) and atropine
(0.01 mg/kg). After satisfactory recovery, patients wereextubated and transferred to the post-anesthesia care unit
(PACU)where they weremonitored with ECG,NIBP and pulse
oximetry.
Assessment of postoperative pain, sedation, hemodynamic
variables such as heart rate (HR) and mean arterial pressure
(MAP), postoperative monitoring of arterial SpO2 and side
effects (e.g. nausea, vomiting, pruritus, respiratory depression
and hemodynamic instability) was done 30 min, 1, 2, 6 and
12 h postoperatively.
Postoperative pain was evaluated based on visual analogue
scale, and first time to ask for rescue analgesia and total pethi-
dine requirements (mg) in 12 h postoperatively was also
recorded. Assessment of sedation was according to sedation
score (Ramsay sedation score) [25].
Hypotension was considered if there was 20% decrease
below the baseline for mean arterial blood pressure, and it
was treated with intravenous ephedrine (3–6 mg IV bolus).
Bradycardia (heart rate <55 beats/min) was treated with intra-
venous atropine (0.6–1 mg). If there was a decrease in arterial
SpO2 (<90%), it was treated with oxygen through a transpar-
ent face mask. Severe nausea or vomiting was treated with dex-
amethasone 5 mg and severe pruritus was treated with
clemastine (TavegylR) 2 mg/ampoule i.v. as required. If any
of the patients developed respiratory depression, the transder-
mal patch was removed and intermittent doses of naloxone
0.4 mg i.v. were administered.
Patient’s satisfaction was done by asking the patient to
answer the question, ‘How would you rate your experience
after the surgery?’ using a 7-point Likert verbal rating scale
(Fig. 1) [26]. Surgeons were also asked to rate their satisfaction
with operative conditions, using the 7-point Likert verbal rat-
ing scale at the end of surgery, acceptable satisfaction score of
both the patient and surgeon being 5–7. Intraoperative bleed-
ing was assessed by bleeding scale (0–5) (Table 2) [27], accept-
able bleeding score being 0–2.
Hormonal stress response was assessed through recording
plasma cortisol (ug/dl) 2 h postoperatively. Serum cortisol
was measured by a Fluorescence Polarization Immunoassay
Technology (FPIA) by the Abbott AXSYM system with the
following reference ranges (morning serum cortisol 4.2–
38.4 ug/dl and evening serum cortisol 1.7–16.6 ug/dl).
2.1. Analysis of data
Using PASS 11 for sample size calculation, in a one-way
ANOVA study it was calculated that a sample size of 19 patients
per group will achieve 82%power to detect a mean difference of
50 mg in total Pethidine consumption with a SDof 25 using an F
test with a 0.05 significance level. 20 patients per group were
intended to be included to replace any dropouts.
Data were analyzed using SPSS 21.0 for Windows (SPSS,
Chicago, IL, USA). Analysis of variance was used to compare
the three groups for quantitative parametric data with post hoc
Tukey’s test performed if there was a significant difference
among the groups, a Kruskal–wallis test was used for quanti-
tative nonparametric data. Chi-square test was used for com-
parison of qualitative data. Continuous parametric data were
presented as mean ± SD, nonparametric data as median
(IQR) and categorical data were presented as number of
patients. P-values of <0.05 were considered statistically
significant.
1   2 3 4 5 6 7  
Extremely dissatisfied   Dissatisfied Somewha t dissatisfied    Undecided         Somewhat satisfied       Satisfied Extremely satisfied 
Likert scale: 
Figure 1 A 7-point Likert-like verbal rating scale for assessment of patients’ and surgeons’ satisfaction.
Table 2 Intraoperative bleeding score classification.
Score Descriptions
0 No bleeding
I Slight bleeding, no suctioning of blood required
II Slight bleeding, occasional required suctioning. Surgical
field not threatened
III Slight bleeding, frequent suctioning required. Bleeding
threatens surgical field a few seconds after suction is
removed
IV Moderate bleeding, frequent suctioning required. Bleeding
threatens surgical field directly after suction is removed
V Severe bleeding, constant suctioning required. Bleeding rate
is faster than its removal by suctioning as surgical field is
severely threatened and surgery becoming impossible
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A total of 67 patients were assessed for eligibility from April
2013 to July 2015 (Fig. 2), out of which 62 patients received
study medication after randomization, 60 patients completed
the study (20 patients for each group) and their data were5 paents 
excluded
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w
rand
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All 
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67 paents were asses
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Figure 2 Flowchart of pincluded in the final analysis (Fig. 2). Five patients were not
included in this study on account of patient’s refusal
(2 patients) and history of chronic analgesic consumption
(3 patients). Two patients were considered as dropouts after
initial randomization and were therefore not subjected to
further statistical analysis (the two patients needed
re-exploration on account of the postoperative bleed).
Results of the current study did not show significant differ-
ence in the demographic data of the groups of patients as
regards age, body weight, height, ASA physical status and
the length of surgery in minutes as shown in Table 3.
No significant differences in HR between the three groups
were recorded at any time postoperatively as shown in
Fig. 3. There were lower recorded values in the mean heart rate
in the TDN and the TDM groups compared to C group,
30 min, 1 h, 2 h and 6 h postoperatively and this wasn’t signif-
icant. There was a decrease in the mean heart rate in the TDN
group compared to the C and the TDM groups 12 h postoper-
atively and this wasn’t significant.
There was a significant decrease in the mean arterial blood
pressure in the TDM group compared to the C and the TDN
groups, 30 min, 1 h, 2 h and 6 h postoperatively as shown
in Fig. 4.aents 
ere 
omized
21 paents in 
TDM group
20 paents 
completed 
the study
1 Dropout
21patients in 
TDN group  
sed for 
ts
aents 
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atients (study design).
Table 3 The demographic data.
Variables C group (n= 20) TDN group (n= 20) TDM group (n= 20) p-value
Age (yr.) 43.6 ± 3.39 43.1 ± 2.4 44.3 ± 1.86 0.357
Weight (kg) 76.4 ± 6.5 77.45 ± 5.1 78.15 ± 2.9 0.188
Height (cm) 168.4 ± 3.4 171.2 ± 3.4 167.5 ± 72.9 0.2
ASA (I/II) 11/9 13/7 12/8 0.9
Duration of anesthesia (min) 111.2 ± 3.4 112.8 ± 4.4 111.4 ± 3.78 0.756
Data were presented as mean ± SD. ASA: American Society of Anesthesiologists.
P> 0.05 was considered statistically non-significant between the 3 groups.
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Figure 3 The heart rate changes (beats/minute). Lines are mean
HR and error bars are SD.
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Figure 4 The mean arterial blood pressure changes (mmHg).
Lines are mean MABP and error bars are SD. *denotes significant
difference.
Figure 5 Sedation score (Ramsay sedation score). The middle
black solid line represents the median RSS score, the upper and
lower margins of the boxes are (IQR) and the whiskers are
minimum and maximum.
 * 
*  * 
 * 
* 
0 
1 
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4 
5 
6 
7 
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S
Axis Title
VAS
group C
group TDN
group TDM
Figure 6 Visual analogue scale (VAS). Columns are median and
error bars are (IQR). *denotes significant difference.
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studied groups throughout the study period (P> 0.05).
The sedation score was significantly higher in TDM group
compared to the C and the TDN groups, 30 min, 1, 2, and 6 h
postoperatively as shown in Fig. 5.
There were significantly lower recorded values in visual
analogue scale in the TDN group and TDM group in compar-
ison with C group, 30 min, 1, 2 and 6 h postoperatively. Pain
score was lower in the TDN group compared to the C and
the TDM groups, 12 h postoperatively and this was not signif-
icant as shown in Fig. 6.
As regards side effects in our study, all cases of the 3 groups
were hemodynamically stable, no patient developed hypoxia
and there were no reported intraoperative complications inter-
fering with the course of surgery or interrupting the surgeons.
Two patients in the C group suffered from nausea (p= 0.01).In the TDN group, the postoperative nausea and vomiting
(PONV) occurred as follows: nausea (8 cases, p= 0.004) and
vomiting (4 cases, p= 0.009), in spite of preoperative granise-
tron (1 mg IV) was given as a prophylactic antiemetic and
there were no reported cases of erythema, respiratory depres-
sion or pruritus. In the TDM group, two patients were dizzy
(p= 0.104).
Table 4 Postoperative data.
Postoperative Data. C group (n= 20) TDN group (n= 20) TDM group (n= 20) p-value
Time for 1st rescue analgesic (minutes) postop 50 .8 ± 19.56y 231.5 ± 11.6 212 ± 12.6 <0.001*
Total pethidine requirements (mg) 12 h postop 122.15 ± 6.38y 55.5 ± 3.97 59.7 ± 4.43 <0.001*
Serum cortisol 2 h postop. (lg/dl) 30.85 ± 3.57y 20.8 ± 3.3 20.65 ± 3. 69 <0.001*
Patient’s satisfaction score 2 (2–2.75) y 6 (4.25–6) 6 (5–6) <0.001*
Intraoperative bleeding (0–2) 15(60%) 17(68%) 20(80%) 0.021*
Surgeon’s satisfaction score 4 (4–4.75) 4 (4–4.75) 7 (6–7) <0.001*
Data are presented as mean (SD), median (interquartile range) or number (%).
P< 0.001 is considered statistically significant between the 3 groups.
* Denotes significant difference.
y P< 0.001 was considered statistically significant between TDN and TDM groups and C group.
 P< 0.001 was considered statistically significant between C and TDN groups and TDM group.
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the TDN and the TDM groups in comparison with C group
as regards the time for 1st rescue analgesic (minutes) postop,
the total pethidine requirements (mg) 12 h postop, the serum
cortisol (lg/dl) 2 h postop and the patient’s satisfaction score.
Intraoperative bleeding measured by bleeding scale was statis-
tically significant less in the TDM group than in the C and the
TDN groups. The surgeon’s satisfaction score was significantly
higher in the TDM group compared to the C and the TDN
groups as shown in Table 4.
4. Discussion
In the present study, there was an overall significant reduction
in the VAS score in the TDN and TDM groups when com-
pared with the C group in the 1st 6 h postoperatively. Even
in the next 6 h where there was no significant reduction in
the VAS, it was still lower in the TDN group than the C and
TDM groups. This reduction in the VAS score was associated
with significant delay in the postoperative time for 1st rescue
analgesic (minutes), significant reduction in the postoperative
total pethidine requirements (mg) 12 h postoperatively, signif-
icant reduction in the 2 h postoperative serum cortisol (lg/dl)
and the significant increase in the postoperative patient’s satis-
faction score as compared with the group C.
Also, this study revealed that the sedation score was signif-
icantly higher in group (III) compared to groups (I) and (II)
30 min, 1, 2, and 6 h postoperatively.
The choice of the transdermal delivery system of nicotine
with a predicted delivery rate of 15 mg/16 h was based on a
limitation mentioned by Habib et al. who stated that the pre-
operative application of a 7 mg nicotine patch resulted in a sig-
nificant reduction in postoperative opioid consumption in
nonsmoking men undergoing radical retropubic prostatectomy
(RRP) under general anesthesia to establish whether there is
a dose–response relationship for the analgesic effect of
nicotine [28].
The current study was based on a selective basis to equalize
intragroup difference and to allow evaluation of the effect of
the study drug. All patients were chosen to be female patients
because of difference in pain thresholds between both genders,
which was previously proved to be significantly higher in
female patients who mostly consume more rescue analgesia
than in male patients and was attributed to higher levels of
apprehension [29,30]. In one study, a transdermal nicotinepatch delivered 7 mg/24 h to nonsmokers and 21 mg/24 h to
smokers, and nicotine increased the pain threshold and
tolerance ratings of men but had no effect on the pain ratings
of women [31]. Current smokers were excluded from the study
depending on the study by Olson et al. who indicated
that transdermal nicotine, 5–15 mg, failed to relieve PO
pain or reduce opioid use in smokers [14]. In addition,
Richardson et al. documented that the analgesic or enhanced
nociceptive effect of nicotine may depend on tobacco use
history [32].
These results are in agreement with the findings of Habib
et al. who found that patients underwent radical retropubic
prostatectomy and were treated with preoperative TDN patch
7 mg showed significantly lower cumulative morphine con-
sumption at 24 h [28]. Our results were also supported with
the study by Ahmed Nagy and ElKadi who demonstrated that
using TDN patch (5 mg/16 h) as an analgesic modality adjunc-
tive to thoracic epidural analgesia (TEA) for patients undergo-
ing thoracotomy was accompanied by significantly lower VAS
scores and significantly lower consumption of rescue analgesia
in patients who received nicotine patch compared with those
who received placebo [33]. These results coincide with the
study by Ali and Sakr who reported that pre-emptive applica-
tion of transdermal 7 mg nicotine patch 2 h before surgery,
had an analgesic effect in patients undergoing lumber disk sur-
gery reducing the intra-operative fentanyl requirements and
postoperative cumulative morphine consumptions and led to
improved pain control [34]. Yagoubian et al., documented that
preoperatively administered nicotine nasal spray (3 mg) was
associated with a highly significant decrease in pain reported
during the 5 days after third molar surgery [35].
In contrast to our results, the systematic review conducted
by Mishriky and Habib documented that the perioperative
nicotine administration was associated with a statistically
insignificant reduction in pain scores at 24 h but with statisti-
cally significant reduction in cumulative opioid consumption
at 24 h, an effect that seemed to be limited to nonsmokers
and concluded that these data do not support a role for nico-
tine in perioperative analgesia. However, the results of this
meta-analysis were limited by the heterogenicity of studies col-
lected, as among the included nine studies TDN was used in six
studies and nicotine nasal spray in three studies; hence, the
effect of route of administration was neglected and TDN as
a slow-release form provides different nicotine blood level
and subsequent longer duration of action [36].
Comparative study between transdermal nicotine and melatonin patches 305These results were in agreement with the findings of
Radwan et al. who reported that pre-emptive oral dose of
6 mg of melatonin reduced the pain scores and pethidine
requirements in the first postoperative 24 h in patients under-
going abdominal surgery [37].
Borazaa et al. also documented that preoperative oral mela-
tonin 6 mg, the night before and 1 h before surgery, decreased
pain scores and tramadol consumption and enhanced sleep
quality and sedation scores during the postoperative period
in patients undergoing elective prostatectomy [38]. These
results were consistent with Caumo et al. who found that
5 mg oral melatonin, the night before and 1 h before surgery
in patients undergoing abdominal hysterectomy, decreased
pain and anxiety during the first 24 h after surgery [39].
These results were partially consistent with Khezri and
Merate who reported that sublingual melatonin 3 mg premed-
ication (60 min before surgery) for patients undergoing catar-
act surgery under topical anesthesia reduced the anxiety
scores in patients and they could not demonstrate that mela-
tonin has a decreasing effect on pain scores [40].
The significant increase in the postoperative patient’s satis-
faction score in TDM group as compared with the group C
could be a consequence of melatonin’s effects on pain and anx-
iety which enhance sleep wake cycle disruption in stressful sit-
uations such as surgeries, providing better recovery quality
[38]. Clinical trials on the effect of melatonin on delirium in
hip fracture patients are going on. Melatonin has been used
successfully to treat and prevent postoperative delirium [40].
Also, the significant increase in the postoperative patient’s sat-
isfaction score in TDN group as compared with the group C
was supported by the study by Ali and Sakr who documented
that the higher response shown in their study in nicotine group
versus control group was marginally significant [34].
No significant differences in HR between the three groups
were recorded at any time. There was a significant decrease
in the mean arterial blood pressure in group (III) compared
to groups (I) and (II) 30 min, 1 h, 2 h and 6 h postoperatively.
Although nicotine has the potential to increase heart rate and
blood pressure because it activates autonomic as well as central
cholinergic receptors [39], the current study did not show any
significant difference in postoperative heart rate or blood pres-
sure measurements with transdermal nicotine application ver-
sus placebo treatments. These results coincide with previous
studies by Flood and Daniel; Habib et al.; Hong et al.; Turan
et al. and Ali and Sakr in which the authors hypothesized that
autonomic stimulation may have been offset by the fact that
patients treated with nicotine were in less pain than those trea-
ted with placebo [41,28,42,43,34].
In contrast to our results, the study by Ahmed Nagy and
ElKadi who found that the sympathetic activating properties
of nicotine with concomitant tachycardia and elevation of
blood pressure were found to be advantageous for competing
epidural sympatholytic effect and hence minimized decrease
in blood pressure [33].
These results were supported by the study by Ismail and
Mowafi who reported that the mean arterial pressure was
decreased after melatonin pre-medication and extended to
the early postoperative period. This mild hypotensive effect
of melatonin may be beneficial in elderly patients, particularly
those at cardiovascular risk [22].
Previous studies showed that melatonin could decrease
MAP in healthy women [44] and men [45]. The mechanismof action of melatonin on circulation is complex and unclear.
Melatonin may bind to specific melatonin receptors in the
blood vessels, interfering with the vascular response to cate-
cholamine [46]. Furthermore, melatonin may interfere with
the peripheral and central autonomic system, causing a
reduction in adrenergic outflow and catecholamines levels
[47]. In addition, it may induce relaxation of the smooth
muscle of the arterial walls via increasing nitric oxide
availability [48].
Intraoperative bleeding was significantly less in TDM
group as compared to C and TDN groups. Intraoperative
hypotension effectively decreases surgical blood loss and
improves surgical field exposure which is essential for spinal
surgeries. This result explained significant increase in the sur-
geon’s satisfaction score in TDM group compared to C and
TDN groups.
As regards side effects in our study, all cases of the 3 groups
were hemodynamically stable, no patient developed hypoxia
and there were no reported intraoperative complications inter-
fering with the course of surgery or interrupting the surgeons.
Two patients in the C group suffered from nausea (p> 0.05).
In the TDN group, the postoperative nausea and vomiting
(PONV) occurred as follows: nausea (8 cases, p< 0.05) and
vomiting (4 cases, p< 0.05), in spite of preoperative granise-
tron (1 mg IV) was given as a prophylactic antiemetic and
there were no reported cases of erythema, respiratory depres-
sion or pruritus. In the TDM group, three patients were dizzy
(p> 0.05).
These results were coincident with the findings of Green-
land et al. who documented a meta-analysis involving patients
participating in randomized trials of transdermal nicotine
replacement therapy suggested that acute nicotine exposure
can cause nausea in some settings and sleep disturbances [49].
The frequency of occurrence of PONV was in agreement
with the findings of Habib et al. (n= 29/44, v= 7/44 cases),
Vibe Nielsen et al. and Ahmed Nagy and ElKadi (n and
v = 18/50 cases) who documented that nicotine seems to
increase the occurrence of nausea and vomiting [28,50,33].
As regards adverse effects in patients who received TDM,
patients were more sedated (P< 0.05) and two patients were
dizzy (p> 0,05). These results were nearly similar to the
results proved by Ismail and Mowafi who found that one
patient in their melatonin group ((1/20 cases) complained of
dizziness [22].5. Limitations of the study
Our study presented several limitations. First, the results did
not allow for an evaluation of the effectiveness of TDN or
TDM in all types of surgery. The second limitation was the
small sample size preventing achievement safety conclusions.
The third limitation of our study was that we did not measure
nicotine and melatonin plasma levels so the interaction
between both agents and endogenous melatonin could not be
assessed. The fourth limitation was the use of one concentra-
tion of the nicotine patch; therefore, we were unable to estab-
lish whether there is a dose–response relationship for the
analgesic effect of nicotine. The fifth limitation of our study
was the patient population including nonsmoking women
only. The results might not be, therefore, extrapolated to
men or to smokers.
306 I.M. Esmat, D.Y. Kassim6. Conclusion
Transdermal administration of nicotine (15 mg/16 h) or trans-
dermal therapeutic system containing 7 mg of melatonin 2 h
preoperatively was an effective, simple, noninvasive, conve-
nient technique and a safe adjuvant for acute postoperative
pain after laparoscopic cholecystectomy. TDN and TDM
allowed delivery of a potent analgesic agent providing a stable
serum concentration for an extended period of time with
acceptable minimal side effects. Prophylactic antiemetics were
advocated to guard against the high possibility of development
of nausea and/or vomiting after application of TDN patch.
7. Recommendations
The use of the TDN or TDM patches as a component of a
multimodal analgesic system (i.e. in conjunction with regional
blocks, a non-steroidal anti-inflammatory drug (NSAID), an
acetaminophen or an a-agonist) may provide an effective post-
operative analgesic regimen.
8. Clinical trial registration
ClinicalTrials.gov Identifier: NCT02747628.
9. Conflict of interest
None.
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